Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.610
-0.020 (-3.17%)
At close: Apr 28, 2026, 4:00 PM EDT
0.604
-0.006 (-0.95%)
After-hours: Apr 28, 2026, 4:45 PM EDT
Barinthus Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
24.92M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBRNS News
- 6 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 7 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 7 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 11 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 1 year ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 1 year ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 1 year ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 1 year ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire